Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study
Lung Non-Small Cell Carcinoma Lung Non-Small Cell Squamous Carcinoma Lung Non-Squamous Non-Small Cell Carcinoma Stage IB Lung Cancer AJCC v7 Stage IB Lung Squamous Cell Carcinoma AJCC v7 Stage II Lung Cancer AJCC v7 Stage II Lung Squamous Cell Carcinoma AJCC v7 Stage IIA Lung Cancer AJCC v7 Stage IIA Lung Squamous Cell Carcinoma AJCC v7 Stage IIB Lung Cancer AJCC v7 Stage IIB Lung Squamous Cell Carcinoma AJCC v7 Stage IIIA Lung Cancer AJCC v7 Stage IIIA Lung Squamous Cell Carcinoma AJCC v7 Carcinoma Lung Neoplasms Carcinoma, Squamous Cell Carcinoma, Non-Small-Cell Lung Gemcitabine Paclitaxel Cisplatin Carboplatin Pembrolizumab Pemetrexed Albumin-Bound Paclitaxel Gemcitabine Hydrochloride Observation Pemetrexed Disodium Quality-of-Life Assessment
Lead Scientists at UC Cancer
- Lyudmila A. Bazhenova (ucsd)
Dr. Bazhenova’s clinical practice and research concentrate on lung cancer, particularly as this relates to females and non-smokers. She actively participates in cooperative group trials, and takes an active role in designing and implementing clinical investigations, including phase II studies and correlative science projects with several UCSD investigators.
- Karen L. Kelly (ucdavis)
Professor, Hematology and Oncology. Authored (or co-authored) 166 research publications.
- accepting new patients
- Start Date
- Completion Date
- National Cancer Institute (NCI)
- Phase 3
- Study Type
- Last Updated